Newsletters and Deep Dive digital magazine
Gilead Sciences has claimed FDA
New research from ViiV Healthcare has revealed a widespread gap in public knowledge and understanding of HIV worldwide, with
GlaxoSmithKline' majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis (PrE
Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug islatravir, raising another warning flag about the highly-touted therapy.
People living with HIV in England and Wales now have an alternative to daily oral tablets, after NICE backed NHS use of two long-acting injectable therapies developed by ViiV Healthcare and
Gilead Sciences has filed for FDA approval of a long-acting therapy for resistant HIV infections that only needs to be administered once every six months.
Just weeks after Roche pharma chief Bill Anderson resigned to seek other opp
Our website has served us well over the years, but after five years since the last re-design – during which aesthetic standards have changed and website technology has improved